Skip to content

A Study to Evaluate the Efficacy and Safety of HRS4800 Tablets for Postoperative Analgesia After Impacted Teeth Removal Surgery.

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of HRS4800 Tablets for Postoperative Analgesia After Impacted Teeth Removal Surgery

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05318846
Enrollment
38
Registered
2022-04-08
Start date
2022-01-14
Completion date
2022-03-22
Last updated
2022-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Brief summary

The study is being conducted to evaluate the efficacy and safety of HRS4800 tablets for postoperative analgesia after impacted teeth removal surgery.

Interventions

Dosing frequency: single dose; Route of administration: oral

DRUGPlacebo tablets

Dosing frequency: single dose; Route of administration: oral

Sponsors

Jiangsu HengRui Medicine Co., Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

A multicenter, randomized, double-blind, placebo-controlled, phase IIa clinical trial

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. 18 to 65 years old. 2. Scheduled to remove the impacted tooth. 3. Any NRS score ≥5 within 4 hours after the surgery. 4. Willing to comply with the study procedures and requirements. 5. Willing and able to provide written informed consent for this study.

Exclusion criteria

1. Subjects who had used other drugs that affect the analgesic effect. 2. Subjects who have infection or other complications on the planned oral surgical site. 3. Subjects with uncontrolled hypertension or hypotension. 4. Subjects with severe cardiovascular and cerebrovascular diseases. 5. Subjects with severe gastrointestinal disease. 6. Subjects with a history of drug or alcohol abuse. 7. Subjects with significant abnormal electrocardiogram. 8. Subjects with significant abnormal laboratory value. 9. Subject who were allergic to the study drug and ingredients. 10. Pregnancy, lactation or having recent pregnant plan. 11. Subjects who participated in other clinical research study 30 days before entering this study. 12. Other conditions unsuitable for participation in the study.

Design outcomes

Primary

MeasureTime frame
the Sum of Pain Intensity Differences (SPID) using numerical rating scale (NRS, ranging from 0-10, the larger the number, the more severe the pain) 0-8 hours after drug administration0-8 hours after drug administration

Secondary

MeasureTime frame
the Sum of Pain Intensity Differences (SPID) using numerical rating scale (NRS, ranging from 0-10, the larger the number, the more severe the pain) 0-4 hours after drug administration0-4 hours after drug administration
the Sum of Pain Intensity Differences (SPID) using numerical rating scale (NRS, ranging from 0-10, the larger the number, the more severe the pain) 0-12 hours after drug administrationadministration0-12 hours after drug administration
Pain relief degree at each evaluating timepoint using pain relief scale (PAR, ranging from 0-4, the larger the number, the more obvious the pain relief) after drug administration0-12 hours after drug administration
Sum of pain relief degree within 4 hours using pain relief scale (PAR, ranging from 0-4, the larger the number, the more obvious the pain relief) after drug administration (SPAR)0-4 hours after drug administration
Sum of pain relief degree within 8 hours using pain relief scale (PAR, ranging from 0-4, the larger the number, the more obvious the pain relief) after drug administration (SPAR)0-8 hours after drug administration
the Differences of Pain Intensity (PID) form each evaluating timepoint to baseline using numerical rating scale (NRS, ranging from 0-10, the larger the number, the more severe the pain) after drug administration0-12 hours after drug administration
Proportion of subjects who reaches a 50% reduction in pain intensity from baseline using numerical rating scale (NRS, ranging from 0-10, the larger the number, the more severe the pain) at each evaluating timepoint0-12 hours after drug administration
Time from drug administration to the first NRS score≤30-12 hours after drug administration
Time from drug administration to the first use of rescue medication0-12 hours after drug administration
Proportion of subjects who receive rescue therapy during the treatment period0-12 hours after drug administration
Subject's overall satisfaction score of the study medication using subject satisfaction scale (ranging from 0-10, the larger the number, the higher the satisfaction)12 hours after drug administration
Sum of pain relief degree within 12 hours using pain relief scale (PAR, ranging from 0-4, the larger the number, the more obvious the pain relief) after drug administration (SPAR)0-12 hours after drug administration

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026